Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.
复制标题
DOI：
10.18632/oncotarget.17262
复制
发表时间：
2017-08-15
期刊：
影响因子：
--
通讯作者：
Ruggeri EM
中科院分区：
文献类型：
--
作者：
Moscetti L;Fabbri MA;Natoli C;Vici P;Gamucci T;Sperduti I;Iezzi L;Iattoni E;Pizzuti L;Roma C;Vaccaro A;D'Auria G;Mauri M;Mentuccia L;Grassadonia A;Barba M;Ruggeri EM
The observational prospective trial herein presented aimed at evaluating the efficacy of fulvestrant 500 mg in the treatment of endocrine sensitive advanced breast cancer patients from the real world setting. The primary end point was clinical benefit rate (CBR). Secondary end points were overall survival (OS), progression free survival (PFS) and tolerability. One hundred sixty three patients were enrolled. At a median follow up of 20 months, the 61% of patients reached CBR, whose median duration was 10.8 months. Median PFS and OS were 7 and 35 months, respectively. Endocrine sensitive patients showed better PFS and OS. No relevant toxicity appeared when analyzing safety data. In multivariate analysis, visceral involvement, endocrine sensitivity and previous endocrine therapy were prognostic factor for PFS, whereas endocrine sensitivity and metastasis at diagnosis had prognostic relevance for OS. Estrogen receptor expression >50%, single metastatic site, and no prior endocrine therapy for advanced disease were predictive of CBR. In this prospective trial, fulvestrant 500 mg appeared to be a safe and active treatment and confirmed its efficacy in the daily clinical practice. A high percent expression of estrogen receptors (above 50%) was associated with higher CBR. Treatment was very well tolerated. Endocrine sensitivity had a major impact on treatment outcome. As expected, patients who had received first-line endocrine therapy for advanced disease exhibited worse outcome and a lower CBR.
登录
查看更多内容
DOI：
10.1200/jco.2015.61.5831
发表时间：
2015-11-10
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Ellis MJ;Llombart-Cussac A;Feltl D;Dewar JA;Jasiówka M;Hewson N;Rukazenkov Y;Robertson JF
通讯作者：
Robertson JF
DOI：
10.1093/jnci/djt337
发表时间：
2014-01
期刊：
Journal of the National Cancer Institute
影响因子：
--
作者：
Di Leo A;Jerusalem G;Petruzelka L;Torres R;Bondarenko IN;Khasanov R;Verhoeven D;Pedrini JL;Smirnova I;Lichinitser MR;Pendergrass K;Malorni L;Garnett S;Rukazenkov Y;Martin M
通讯作者：
Martin M
影响因子：
10.3
作者：
Brewster, Abenaa M.;Hortobagyi, Gabriel N.;Esteva, Francisco J.
通讯作者：
Esteva, Francisco J.
影响因子：
3.2
作者：
Das, Romita;Cope, Shannon;Howlett, Matthew
通讯作者：
Howlett, Matthew
影响因子：
45.3
作者：
Jatoi, Ismail;Chen, Bingshu E.;Rosenberg, Philip S.
通讯作者：
Rosenberg, Philip S.